917 related articles for article (PubMed ID: 8035346)
21. Regulation of cardiac and renal mineralocorticoid receptor expression by captopril following myocardial infarction in rats.
de Resende MM; Kauser K; Mill JG
Life Sci; 2006 May; 78(26):3066-73. PubMed ID: 16413583
[TBL] [Abstract][Full Text] [Related]
22. Effects of captopril on cardiac and renal damage, and metabolic alterations in the nitric oxide-deficient hypertensive rat.
Khattab MM; Mostafa A; Al-Shabanah O
Kidney Blood Press Res; 2005; 28(4):243-50. PubMed ID: 16220007
[TBL] [Abstract][Full Text] [Related]
23. Determinants of in vivo activity of neutral endopeptidase 3.4.24.11 and angiotensin converting enzyme inhibitors.
Seymour AA; Asaad MM; Abboa-Offei BE; Smith PL; Rogers WL; Dorso CR
J Pharmacol Exp Ther; 1996 Feb; 276(2):708-13. PubMed ID: 8632340
[TBL] [Abstract][Full Text] [Related]
24. Bradykinin metabolism in rat hearts with left-ventricular hypertrophy following myocardial infarction.
Dumoulin MJ; Adam A; Rouleau JL; Gosselin H; Lamontagne D
Can J Physiol Pharmacol; 2003 Jul; 81(7):740-6. PubMed ID: 12897822
[TBL] [Abstract][Full Text] [Related]
25. Effect of high salt intake on local renin-angiotensin system and ventricular dysfunction following myocardial infarction in rats.
de Resende MM; Mill JG
Clin Exp Pharmacol Physiol; 2007 Apr; 34(4):274-9. PubMed ID: 17324137
[TBL] [Abstract][Full Text] [Related]
26. Reversal of cardiac hypertrophy and fibrosis by S21402, a dual inhibitor of neutral endopeptidase and angiotensin converting enzyme in SHRs.
Farina NK; Johnston CI; Burrell LM
J Hypertens; 2000 Jun; 18(6):749-55. PubMed ID: 10872560
[TBL] [Abstract][Full Text] [Related]
27. Combined angiotensin-converting enzyme inhibition and adrenomedullin in an ovine model of heart failure.
Rademaker MT; Charles CJ; Cooper GJ; Coy DH; Espiner EA; Lewis LK; Nicholls MG; Richards AM
Clin Sci (Lond); 2002 Jun; 102(6):653-60. PubMed ID: 12049620
[TBL] [Abstract][Full Text] [Related]
28. The effect of acute angiotensin-converting enzyme and neutral endopeptidase 24.11 inhibition on plasma extravasation in the rat.
Sulpizio AC; Pullen MA; Edwards RM; Brooks DP
J Pharmacol Exp Ther; 2004 Jun; 309(3):1141-7. PubMed ID: 14769834
[TBL] [Abstract][Full Text] [Related]
29. Antihypertensive action of a novel orally active angiotensin converting enzyme inhibitor altiopril calcium (MC-838) in several hypertensive models of rats: comparison with captopril.
Aono J; Koga T; Yamazaki T; Shiraki Y; Sakai K
Arch Int Pharmacodyn Ther; 1988; 292():203-22. PubMed ID: 3293542
[TBL] [Abstract][Full Text] [Related]
30. Effect of chronic captopril treatment on circulating and tissue renin-angiotensin system in SHR rats.
Hu WY; Chen DG; Chen SC; Jin XQ; Wang HJ
Zhongguo Yao Li Xue Bao; 1996 Nov; 17(6):507-12. PubMed ID: 9863143
[TBL] [Abstract][Full Text] [Related]
31. Cardiorenal consequences of dual angiotensin converting enzyme and neutral endopeptidase 24.11 inhibition in transgenic rats with an extra renin gene.
Wegner M; Hirth-Dietrich C; Knorr A; Dressel J; Ganten D; Stasch JP
Hypertens Res; 1996 Sep; 19(3):151-9. PubMed ID: 8891743
[TBL] [Abstract][Full Text] [Related]
32. Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension.
Pham I; Gonzalez W; el Amrani AI; Fournié-Zaluski MC; Philippe M; Laboulandine I; Roques BP; Michel JB
J Pharmacol Exp Ther; 1993 Jun; 265(3):1339-47. PubMed ID: 8389863
[TBL] [Abstract][Full Text] [Related]
33. Regression of ventricular and vascular hypertrophy: are there differences between structurally different angiotensin-converting enzyme inhibitors?
Raasch W; Bartels T; Schwartz C; Häuser W; Rütten H; Dominiak P
J Hypertens; 2002 Dec; 20(12):2495-504. PubMed ID: 12473875
[TBL] [Abstract][Full Text] [Related]
34. ACE inhibition and protection from doxorubicin-induced cardiotoxicity in the rat.
Sacco G; Mario B; Lopez G; Evangelista S; Manzini S; Maggi CA
Vascul Pharmacol; 2009; 50(5-6):166-70. PubMed ID: 19344651
[TBL] [Abstract][Full Text] [Related]
35. [Experimental myocardial infarction in the rat. Effect of perindopril].
Michel JB
Arch Mal Coeur Vaiss; 1991 Dec; 84 Spec No 4():51-61. PubMed ID: 1665327
[TBL] [Abstract][Full Text] [Related]
36. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
37. Effects of subchronic treatment with trandolapril and enalapril on cardiovascular morphologic alterations in the aged spontaneously hypertensive rat with heart failure.
Secchi J; Lecaque D; Dunn FW; Jouquey S; Auberval UD; Benzoni F; Sirugue O; Hamon G
J Cardiovasc Pharmacol; 1994; 23 Suppl 4():S30-7. PubMed ID: 7527099
[TBL] [Abstract][Full Text] [Related]
38. Effect on prolonged inhibition of neutral endopeptidase on cardiac hypertrophy in rats with myocardial infarction.
Marie C; Mossiat C; Gros C; Monteil T; Bralet J
Cardiovasc Drugs Ther; 1996 Nov; 10(5):593-8. PubMed ID: 8950076
[TBL] [Abstract][Full Text] [Related]
39. Cardioprotective effects of ACE inhibitors: experimental proof and clinical perspectives.
Schölkens BA; Linz W
Clin Physiol Biochem; 1990; 8 Suppl 1():33-43. PubMed ID: 2147878
[TBL] [Abstract][Full Text] [Related]
40. Comparison of irbesartan with captopril effects on cardiac hypertrophy and gene expression in heart failure-prone male SHHF/Mcc-fa(cp) rats.
Carraway JW; Park S; McCune SA; Holycross BJ; Radin MJ
J Cardiovasc Pharmacol; 1999 Mar; 33(3):451-60. PubMed ID: 10069682
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
